Skip to main content
Top
Published in: Cardiology and Therapy 2/2017

Open Access 01-12-2017 | Original Research

Analytical Management of Patients Undergoing Oral Anticoagulant Therapy Could Have a Strong Impact on Clinical Outcomes: A Follow-up Study

Authors: Vincenzo De Iuliis, Sebastiano Ursi, Gianfranco Vitullo, Irma Griffo, Antonio Marino, Marika Caruso, Francesco Cipollone, Sabrina Capodifoglio, Veronica Breda, Elena Toniato, Alfonso Pennelli, Pio Conti, Stefano Martinotti

Published in: Cardiology and Therapy | Issue 2/2017

Login to get access

Abstract

Introduction

Oral anticoagulant therapy, such as vitamin K antagonists (VKAs), is prominent for the prevention of cerebral ischemic stroke or systemic embolism and all-cause mortality in patients with atrial fibrillation, venous thromboembolism, and mechanical or biological valve. VKA treatment requires monitoring of the international normalized ratio (INR) in order to maintain it in a therapeutic range, avoiding side effects, the main and most significant of which is bleeding. The aim of the present study was to evaluate the event rates of several clinical composite outcomes, such as bleeding, thromboembolic events, and all-cause death.

Methods

We compared three organizational models distinguished by a total (from 1 January to 31 December 2015 in which PT/INR analysis with the relative internal and external quality controls was performed by the surveillance center) or partial (from 15 January to 15 July 2016 and from 15 August to 15 November 2016, in which the surveillance center had the ability to view only the PT/INR results or all patients analyses, including blood count, creatinine, liver enzymes, etc., respectively) analytical patient management. The present longitudinal follow-up study included 1225 patients, recruited from 1 January 2015 to 15 November 2016 at a surveillance center for the prevention of cerebral ischemic stroke and systemic embolism in Chieti (Italy).

Results

The results show a significant rise of the incidence rate ratio in patients undergoing VKA treatment during the period 15 January to 15 July 2016 compared to the previous one regarding total bleeding, especially for minor bleeding and digestive bleeding; thromboembolic events; and all-death cause.

Conclusions

These findings show that analytical and clinical data and information should be under the direct supervision and responsibility of the surveillance center. In fact, this approach seems to highlight the best results in terms of safety and therapeutic effectiveness.
Literature
1.
go back to reference Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.CrossRefPubMed Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.CrossRefPubMed
2.
go back to reference Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.CrossRefPubMed Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.CrossRefPubMed
3.
go back to reference Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.CrossRefPubMed Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.CrossRefPubMed
4.
go back to reference Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.CrossRefPubMed Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.CrossRefPubMed
5.
go back to reference AlTurki A, Proietti R, Birnie DH, Essebag V. Management of antithrombotic therapy during cardiac implantable device surgery. J Arrhythm. 2016;32(3):163–9.CrossRefPubMedPubMedCentral AlTurki A, Proietti R, Birnie DH, Essebag V. Management of antithrombotic therapy during cardiac implantable device surgery. J Arrhythm. 2016;32(3):163–9.CrossRefPubMedPubMedCentral
7.
go back to reference Kasperska-Zajac A, Grzanka A, Kowalczyk J, et al. Refractory chronic spontaneous urticaria and permanent atrial fibrillation associated with dental infection: mere coincidence or something more to it? Int J Immunopathol Pharmacol. 2016;29(1):112–20.CrossRefPubMed Kasperska-Zajac A, Grzanka A, Kowalczyk J, et al. Refractory chronic spontaneous urticaria and permanent atrial fibrillation associated with dental infection: mere coincidence or something more to it? Int J Immunopathol Pharmacol. 2016;29(1):112–20.CrossRefPubMed
8.
go back to reference Wipf JE, Lipsky BA. Atrial fibrillation. Thromboembolic risk and indications for anticoagulation. Arch Int Med. 1990;150:1598–1603. Wipf JE, Lipsky BA. Atrial fibrillation. Thromboembolic risk and indications for anticoagulation. Arch Int Med. 1990;150:1598–1603.
9.
go back to reference Menke J, Luthje L, Kastrup A. Thromboembolism in atrial fibrillation. Am J Cardiol. 2010;105:502–10.CrossRefPubMed Menke J, Luthje L, Kastrup A. Thromboembolism in atrial fibrillation. Am J Cardiol. 2010;105:502–10.CrossRefPubMed
10.
go back to reference Steinberg BA, Piccini JP. Anticoagulation in atrial fibrillation. Br Med J. 2014;348:g2116.CrossRef Steinberg BA, Piccini JP. Anticoagulation in atrial fibrillation. Br Med J. 2014;348:g2116.CrossRef
11.
go back to reference Reynolds MW, Fahrbach K, Hauch O. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest. 2004;126:1938–45.CrossRefPubMed Reynolds MW, Fahrbach K, Hauch O. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest. 2004;126:1938–45.CrossRefPubMed
12.
go back to reference Tidjane N, Hachem A, Zaid Y, et al. A primary role for kinin B1 receptor in inflammation, organ damage, and lethal thrombosis in a rat model of septic shock in diabetes. Euro J Inflamm. 2015;13:40–52.CrossRef Tidjane N, Hachem A, Zaid Y, et al. A primary role for kinin B1 receptor in inflammation, organ damage, and lethal thrombosis in a rat model of septic shock in diabetes. Euro J Inflamm. 2015;13:40–52.CrossRef
13.
go back to reference Schneider DJ, Sobel BE. Conundrums in the combined use of anticoagulants and antiplatelet drugs. Circulation. 2007;116:305–15.CrossRefPubMed Schneider DJ, Sobel BE. Conundrums in the combined use of anticoagulants and antiplatelet drugs. Circulation. 2007;116:305–15.CrossRefPubMed
14.
go back to reference Jia XF, Hong Z, Fan JH, Zhang YM. Clinical effect of mechanical fragmentation combined with recombinant tissue plasminogen activator artery thrombolysis on acute cerebral infarction. J Biol Regul Homeost Agents. 2016;30(3):821–6.PubMed Jia XF, Hong Z, Fan JH, Zhang YM. Clinical effect of mechanical fragmentation combined with recombinant tissue plasminogen activator artery thrombolysis on acute cerebral infarction. J Biol Regul Homeost Agents. 2016;30(3):821–6.PubMed
15.
go back to reference Fang Y, Zong HL, Zhang L, Wang ZH, Sun LM, Zhang RF. Vena-venous hemofiltration in treating severe injury-induced multiple organ dysfunction syndrome. J Biol Regul Homeost Agents. 2016;30(2):477–84.PubMed Fang Y, Zong HL, Zhang L, Wang ZH, Sun LM, Zhang RF. Vena-venous hemofiltration in treating severe injury-induced multiple organ dysfunction syndrome. J Biol Regul Homeost Agents. 2016;30(2):477–84.PubMed
16.
17.
go back to reference January CT, Wann LS, Alpert JS. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol. 2014;64:2246–80.CrossRef January CT, Wann LS, Alpert JS. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol. 2014;64:2246–80.CrossRef
18.
go back to reference CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349(9066):1641–9. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349(9066):1641–9.
19.
go back to reference Mascali A, Franzese O, Nisticò S, et al. Obesity and kidney disease: beyond the hyperfiltration. Int J Immunopathol Pharmacol. 2016;29(3):354–63.CrossRefPubMed Mascali A, Franzese O, Nisticò S, et al. Obesity and kidney disease: beyond the hyperfiltration. Int J Immunopathol Pharmacol. 2016;29(3):354–63.CrossRefPubMed
20.
go back to reference Piotrowska Ż, Janiuk I, Lewandowska A, Kasacka I. Decreased immunoreactivity of visfatin in the pancreas and liver of rats with renovascular hypertension. J Biol Regul Homeost Agents. 2016;30(4):1073–8.PubMed Piotrowska Ż, Janiuk I, Lewandowska A, Kasacka I. Decreased immunoreactivity of visfatin in the pancreas and liver of rats with renovascular hypertension. J Biol Regul Homeost Agents. 2016;30(4):1073–8.PubMed
21.
go back to reference Crincoli V, Ballini A, Fatone L, Di Bisceglie MB, Nardi GM, Grassi FR. Cytokine genotype distribution in patients with periodontal disease and rheumatoid arthritis or diabetes mellitus. J Biol Regul Homeost Agents. 2016;30(3):863–6.PubMed Crincoli V, Ballini A, Fatone L, Di Bisceglie MB, Nardi GM, Grassi FR. Cytokine genotype distribution in patients with periodontal disease and rheumatoid arthritis or diabetes mellitus. J Biol Regul Homeost Agents. 2016;30(3):863–6.PubMed
22.
go back to reference Mahmoud MH, Badr G, El Shinnawy NA. Camel whey protein improves lymphocyte function and protects against diabetes in the offspring of diabetic mouse dams. Int J Immunopathol Pharmacol. 2016;29(4):632–46.CrossRefPubMed Mahmoud MH, Badr G, El Shinnawy NA. Camel whey protein improves lymphocyte function and protects against diabetes in the offspring of diabetic mouse dams. Int J Immunopathol Pharmacol. 2016;29(4):632–46.CrossRefPubMed
23.
go back to reference Bianchi E, Ripandelli G, Taurone S, et al. Age and diabetes related changes of the retinal capillaries: an ultrastructural and immunohistochemical study. Int J Immunopathol Pharmacol. 2016;29(1):40–53.CrossRefPubMed Bianchi E, Ripandelli G, Taurone S, et al. Age and diabetes related changes of the retinal capillaries: an ultrastructural and immunohistochemical study. Int J Immunopathol Pharmacol. 2016;29(1):40–53.CrossRefPubMed
24.
go back to reference Adar T, Edden Y, Shteingart S, et al. Portal hypertension is associated with modulation of regulatory T cells. Eur J Inflamm. 2016;14:40–47. Adar T, Edden Y, Shteingart S, et al. Portal hypertension is associated with modulation of regulatory T cells. Eur J Inflamm. 2016;14:40–47.
25.
go back to reference Rietbrock S, Heeley E, Plumb J. Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the congestive heart failure, hypertension, age >75, diabetes mellitus, and prior stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J. 2008;156:57–64.CrossRefPubMed Rietbrock S, Heeley E, Plumb J. Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the congestive heart failure, hypertension, age >75, diabetes mellitus, and prior stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J. 2008;156:57–64.CrossRefPubMed
26.
go back to reference Lip GY, Nieuwlaat R, Pisters R. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.CrossRefPubMed Lip GY, Nieuwlaat R, Pisters R. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.CrossRefPubMed
27.
go back to reference Olesen JB, Lip GY, Hansen ML. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. Br Med J. 2011;342:d124.CrossRef Olesen JB, Lip GY, Hansen ML. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. Br Med J. 2011;342:d124.CrossRef
28.
go back to reference Mant J, Hobbs FD, Fletcher K. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493–503.CrossRefPubMed Mant J, Hobbs FD, Fletcher K. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493–503.CrossRefPubMed
29.
go back to reference Arbring K, Uppugunduri S, Lindhal TL. Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics. BMC Health Serv Res. 2013;7(13):85.CrossRef Arbring K, Uppugunduri S, Lindhal TL. Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics. BMC Health Serv Res. 2013;7(13):85.CrossRef
30.
go back to reference Wieloch M, Själander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J. 2011;32(18):2282–9. Wieloch M, Själander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J. 2011;32(18):2282–9.
31.
go back to reference Wysowski DK, Nourjah P. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Int Med. 2007;167:1414–9.CrossRef Wysowski DK, Nourjah P. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Int Med. 2007;167:1414–9.CrossRef
33.
go back to reference Chow S, Shao J, Wang H. Sample size calculations in clinical research, 2nd ed. Boca Raton: Chapman & Hall/CRC Biostatistic Series. Chow S, Shao J, Wang H. Sample size calculations in clinical research, 2nd ed. Boca Raton: Chapman & Hall/CRC Biostatistic Series.
34.
go back to reference Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–4.CrossRefPubMed Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–4.CrossRefPubMed
35.
go back to reference Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H. Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation: the J-RHYTHM Registry study design. J Cardiol. 2011;57:95–9.CrossRefPubMed Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H. Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation: the J-RHYTHM Registry study design. J Cardiol. 2011;57:95–9.CrossRefPubMed
36.
go back to reference Chuai JB, Shi L, Ma XY, Wu D, Kang K, Jiang SL. Curative effect of mechanical heart valve replacement and anticoagulant therapy after surgery. J Biol Regul Homeost Agents. 2016;30(1):141–6.PubMed Chuai JB, Shi L, Ma XY, Wu D, Kang K, Jiang SL. Curative effect of mechanical heart valve replacement and anticoagulant therapy after surgery. J Biol Regul Homeost Agents. 2016;30(1):141–6.PubMed
37.
go back to reference Yang F, Xiang ML, Liu YM. Thrombin in combination with intensive nursing in treating upper gastrointestinal bleeding in children. J Biol Regul Homeost Agents. 2016;30(2):491–5.PubMed Yang F, Xiang ML, Liu YM. Thrombin in combination with intensive nursing in treating upper gastrointestinal bleeding in children. J Biol Regul Homeost Agents. 2016;30(2):491–5.PubMed
Metadata
Title
Analytical Management of Patients Undergoing Oral Anticoagulant Therapy Could Have a Strong Impact on Clinical Outcomes: A Follow-up Study
Authors
Vincenzo De Iuliis
Sebastiano Ursi
Gianfranco Vitullo
Irma Griffo
Antonio Marino
Marika Caruso
Francesco Cipollone
Sabrina Capodifoglio
Veronica Breda
Elena Toniato
Alfonso Pennelli
Pio Conti
Stefano Martinotti
Publication date
01-12-2017
Publisher
Springer Healthcare
Published in
Cardiology and Therapy / Issue 2/2017
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI
https://doi.org/10.1007/s40119-017-0090-x

Other articles of this Issue 2/2017

Cardiology and Therapy 2/2017 Go to the issue